Prognostic nomogram for patients with BRCA mutation positive platinum-sensitive recurrent ovarian cancer

Progression-free survival

A tool for health care professionals and researchers to prognosticate progression-free survival outcomes in patients with BRCA mutation positive platinum-sensitive recurrent ovarian cancer about to commence with maintenance olaparib therapy


Disclaimer & Privacy

The NHMRC Clinical Trials Centre (CTC) strives to keep information stored in the PSROC Online tool up to date, but does not guarantee the accuracy, reliability or currency of the information. Any errors in the information that are brought to our attention will be corrected as soon as possible. The CTC reserves the right to change at any time without notice any information stored in the PSROC Online tool.


Input Reference

CA-125 at commencement of Olaparib options: <=25 IU/ml, >25 IU/ml
Platinum-free interval options: 6-12 months, >12 months
Presence of disease >=1cm options: No, Yes
Number of previous platinum lines options: 2, >2
Enter your information – all fields are required




Result

These results below provide a guide to inform discussions about progression-free survival (PFS) outcomes for your patients. The results are estimated using data from a group of selected patients enrolled in clinical trials. Caution should be exercised when interpreting these results as your patients may be different from the clinical trial patients.


Predicted probability of PFS at 1 year on placebo (%) :
Predicted median PFS on placebo (months) :
Best case scenario in months :
Worst case scenario in months :
Typical range in months :
Predicted probability of PFS at 1 year on olaparib (%) :
Predicted median PFS on olaparib (months) :
Best case scenario in months :
Worst case scenario in months :
Typical range in months :